ESGV vs XBI
Vanguard ESG US Stock ETF vs SPDR S&P Biotech ETF
- • ESGV has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • ESGV pays a higher dividend yield (0.87%).
Side-by-side metrics
| Metric | ESGV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.87% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $13.18B | $10.73B |
YTD return | 9.48% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.13 | 1.10 |
P/E ratio | 26.89 | — |
Last price | $133.31 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
ESGV top holdings
| NVDA | NVIDIA Corp | 8.36% |
| AAPL | Apple Inc | 7.60% |
| MSFT | Microsoft Corp | 5.65% |
| AMZN | Amazon.com Inc | 4.39% |
| GOOGL | Alphabet Inc Class A | 3.74% |
| AVGO | Broadcom Inc | 3.49% |
| GOOG | Alphabet Inc Class C | 3.01% |
| META | Meta Platforms Inc Class A | 2.34% |
| TSLA | Tesla Inc | 2.08% |
| MU | Micron Technology Inc | 1.84% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About ESGV
ESGV (Vanguard ESG US Stock ETF) is Broad US market with ESG screens applied. Managed by Vanguard, the fund carries $13.2B in assets under management, an expense ratio of 0.09%, a dividend yield of 0.87%. Its largest holding is NVIDIA Corp (NVDA), which represents 8.4% of the portfolio. Real Estate is the fund's largest sector exposure at 2.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.